HighTide Therapeutics Inc (2511.HK)
HKD 1.11
(14.43%)
HKD 1.11
(14.43%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -440.35 Million CNY | -73.59% |
| 2022 | -262.9 Million CNY | -65.16% |
| 2021 | -159.17 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -133.25 Thousand HKD | 0.15% |
| 2024 Q1 | -134.4 Thousand HKD | 99.95% |
| 2023 Q1 | -98.35 Thousand HKD | 99.93% |
| 2023 Q4 | -277.9 Million HKD | -187566.07% |
| 2023 Q3 | -148.08 Thousand HKD | 99.92% |
| 2023 Q2 | -176.18 Million HKD | -179025.41% |
| 2023 FY | -456.39 Million CNY | -73.59% |
| 2022 Q2 | -126.4 Million HKD | 0.0% |
| 2022 FY | -262.9 Million CNY | -65.16% |
| 2022 Q4 | -136.22 Million HKD | 0.0% |
| 2021 FY | -159.17 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 67.76 Million HKD | 749.801% |
| CK Life Sciences Int'l., (Holdings) Inc. | 897.95 Million HKD | 149.04% |